Pages that link to "Q81401055"
Jump to navigation
Jump to search
The following pages link to Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis (Q81401055):
Displaying 50 items.
- Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in Stiff Person Syndrome (Q21136358) (← links)
- New and emerging disease modifying therapies for multiple sclerosis (Q22242305) (← links)
- B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions (Q26770664) (← links)
- Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis (Q26771459) (← links)
- The Ins and Outs of B Cells in Multiple Sclerosis (Q26776542) (← links)
- Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments (Q26851694) (← links)
- Humoral-targeted immunotherapies in multiple sclerosis (Q26865971) (← links)
- Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics (Q26998412) (← links)
- Neuroinflammation: Ways in Which the Immune System Affects the Brain (Q28080620) (← links)
- Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies (Q28282500) (← links)
- Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity (Q28290005) (← links)
- Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis (Q31014036) (← links)
- Primary-progressive multiple sclerosis (Q31130362) (← links)
- The potential utility of B cell-directed biologic therapy in autoimmune diseases (Q33377109) (← links)
- Monoclonal antibody treatments for multiple sclerosis (Q33380819) (← links)
- Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy (Q34110804) (← links)
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial (Q34229618) (← links)
- The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs). (Q34373452) (← links)
- Practical considerations on the use of rituximab in autoimmune neurological disorders (Q34409447) (← links)
- B-cell targeting in rheumatoid arthritis and other autoimmune diseases (Q34514813) (← links)
- Monoclonal antibodies in the therapy of multiple sclerosis: an overview (Q34605605) (← links)
- Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. (Q35539775) (← links)
- Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). (Q35557832) (← links)
- Update on rituximab (Q35579499) (← links)
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients (Q35585366) (← links)
- B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases (Q35903957) (← links)
- The Charcot Lecture | beating MS: a story of B cells, with twists and turns (Q36086475) (← links)
- Lymphoid neogenesis in chronic inflammatory diseases. (Q36405080) (← links)
- MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing (Q36433030) (← links)
- Drug insight: using monoclonal antibodies to treat multiple sclerosis (Q36577212) (← links)
- Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis (Q36639659) (← links)
- Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis (Q36803471) (← links)
- B cells: no longer the nondominant arm of multiple sclerosis. (Q36815384) (← links)
- Emerging therapies for MS. (Q36868435) (← links)
- Emerging therapies for multiple sclerosis (Q36963208) (← links)
- B-cells and humoral immunity in multiple sclerosis. Implications for therapy (Q36981274) (← links)
- Multiple sclerosis therapy: an update on recently finished trials (Q37001453) (← links)
- New developments in understanding and treating neuroinflammation. (Q37057309) (← links)
- Getting specific: monoclonal antibodies in multiple sclerosis. (Q37165875) (← links)
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function (Q37180600) (← links)
- Therapeutic experience of Bing-Neel Syndrome associated with Waldenstrom's macroglobulinemia (Q37223075) (← links)
- Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS (Q37258223) (← links)
- B cells as therapeutic targets in autoimmune neurological disorders (Q37278022) (← links)
- Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary (Q37313911) (← links)
- Disease-modifying agents for multiple sclerosis: recent advances and future prospects (Q37328280) (← links)
- Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis (Q37541906) (← links)
- CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis (Q37579811) (← links)
- A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis (Q37818921) (← links)
- Flow cytometric characterization of cerebrospinal fluid cells (Q37875022) (← links)
- Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. (Q37968620) (← links)